세계의 창약 효소 시장 : 제품 유형, 최종 사용자, 지역별(북미, 유럽, 아시아태평양, 중남미, 중동 및 아프리카) : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2030년)

Persistence Market Research has recently published an in-depth analysis of the global Drug Discovery Enzymes Market, offering a comprehensive overview of key market dynamics, growth drivers, challenges, and emerging trends. This report provides valuable insights into the structure of the Drug Discovery Enzymes Market, presenting exclusive data and statistics that forecast the market's growth trajectory from 2023 to 2030.

The market for drug discovery enzymes is expected to grow steadily, with a projected compound annual growth rate (CAGR) of 7.7%. This expansion will see the market value rise from US$1.8 billion in 2023 to reach US$3 billion by the conclusion of 2030.

Key Insights:

• Drug Discovery Enzymes Market Size (2023E): US$1.8 Bn
• Projected Market Value (2030F): US$3.0 Bn
• Global Market Growth Rate (CAGR 2023 to 2030): 7.7%
• Historical Market Growth Rate (CAGR 2018 to 2022): 5.2%

Drug Discovery Enzymes Market- Report Scope:

Drug discovery enzymes, crucial for creating pharmaceutical compounds, expedite reactions and enhance efficiency in drug development. Sourced from natural origins, they enable the synthesis of complex molecules. With the increasing demand for innovative drugs and advancements in biotechnology, the market has seen significant growth. Enzymes aid in target identification, lead optimization, and drug synthesis. Continuous R&D investments and the adoption of enzymatic technologies are expected to drive further market expansion.

Market Growth Drivers:

The escalating burden of diseases such as cancer, cardiovascular disorders, and infectious diseases worldwide has fueled the demand for effective therapeutics. Notably, cancer, a leading cause of global mortality, accounted for nearly 10 million deaths in 2020. In low- and lower-middle-income countries, infections like human papillomavirus (HPV) and hepatitis contribute to about 30% of cancer cases annually. The rising incidence of diseases has propelled the drug discovery enzymes market. Additionally, significant strides in enzyme engineering techniques have led to the development of new enzyme variants with enhanced catalytic properties and stability. These advancements have expedited the identification and optimization of potential drug candidates.

Market Restraints:

The growth of the market may face constraints due to challenges associated with handling and safety hazards linked to enzymes, including susceptibility to temperature and pH variations. Additionally, financial costs and difficulties in recruiting and retaining participants pose hindrances to market expansion. Inadequacies in the clinical research workforce, challenges imposed by drug sponsors, and concerns about the globalization of clinical research could further impede growth.

Furthermore, the lack of standardization in enzymatic assays and protocols hampers reproducibility and data comparison among research groups. Although efforts to establish standardized protocols are underway, they require further refinement and widespread adoption. Intellectual property rights play a significant role in the drug discovery enzymes market, with securing patent protection being crucial for innovation and investment attraction. However, complex patent landscapes and patent expirations can influence market dynamics.

Market Opportunities:

The continuous advancement in enzyme engineering techniques offers opportunities for developing novel enzyme variants with enhanced catalytic properties, stability, and substrate specificity. These advancements enable the exploration of new applications and improve the efficiency of drug discovery processes. Additionally, the integration of Artificial Intelligence (AI) and machine learning (ML) technologies in drug discovery has the potential to revolutionize the field. AI and ML algorithms can forecast enzyme properties, optimize enzymatic reactions, and create innovative platforms for enzyme-based drug discovery.

Key Questions Answered in the Report:

• What are the key factors driving the growth of the Drug Discovery Enzymes Market?
• Which industry verticals are driving the demand for Drug Discovery Enzymes?
• How are technological advancements reshaping the competitive landscape of the Drug Discovery Enzymes Market?
• Who are the leading players in the global Drug Discovery Enzymes Market?
• What are the emerging trends and future prospects in the global Drug Discovery Enzymes Market?

Competitive Intelligence and Business Strategy:

Leading companies such as Sigma-Aldrich Co. LLC., Kaneka Corporation, and Actelion Pharmaceuticals Ltd are driving innovation in the drug discovery enzymes sector, leveraging their technological expertise and extensive experience in the pharmaceutical industry. These firms prioritize intensive research and development efforts to create cutting-edge enzymes, refine engineering techniques, and expand applications in drug discovery. They focus on enriching their product portfolios with advanced features, extending their market presence, and fostering strong partnerships with pharmaceutical firms and research organizations.

To stand out in this competitive landscape, these companies differentiate their products by offering unique attributes, enhanced precision, and adhering to rigorous regulatory standards and quality assurance measures. This strategic approach helps them attract more customers and gain a competitive advantage over their rivals.

Key Companies Profiled:

• Sigma-Aldrich Co. LLC.
• Kaneka Corporation
• Actelion Pharmaceuticals Ltd
• Genesis Biotechnology Group
• Suven Life Sciences Limited
• Enzo Life Sciences, Inc.
• Merck KGaA
• Apeiron Biologics
• STORM Therapeutics
• Thermo Fisher Scientific
• Abcam

Drug Discovery Enzymes Market Segmentation:

By Product Type:

• Active Kinases
• Ubiquitin
• Epigenetic
• Methyltransferases
• Deacetylases
• Phosphodiesterases
• Other Product Types

By End-User:

• Pharmaceutical and Biotechnology Company
• Research Institutes
• Other End User

By Region:

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Drug Discovery Enzymes Market Snapshot, 2023 and 2030
• 1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. System Location Lifecycle Analysis
• 2.4. Drug Discovery Enzymes Market: Value Chain
  • 2.4.1. List of Raw Material Supplier
  • 2.4.2. List of Manufacturers
  • 2.4.3. List of Distributors
  • 2.4.4. List of Applications
  • 2.4.5. Profitability Analysis
• 2.5. Porter Five Force's Analysis
• 2.6. Geopolitical Tensions: Market Impact
• 2.7. Macro-Economic Factors
  • 2.7.1. Global Sectorial Outlook
  • 2.7.2. Global GDP Growth Outlook
  • 2.7.3. Global Parent Market Overview
• 2.8. Forecast Factors - Relevance and Impact
• 2.9. Regulatory and Technology Landscape

3. Global Drug Discovery Enzymes Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 3.1. Key Highlights
  • 3.1.1. Market Volume (Units) Projections
  • 3.1.2. Market Size and Y-o-Y Growth
  • 3.1.3. Absolute $ Opportunity
• 3.2. Market Size (US$ Mn) Analysis and Forecast
  • 3.2.1. Historical Market Size Analysis, 2013-2016
  • 3.2.2. Current Market Size Forecast, 2018-2026
• 3.3. Global Drug Discovery Enzymes Market Outlook: Product Type
  • 3.3.1. Introduction / Key Findings
  • 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Product Type, 2018 - 2022
  • 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product Type, 2023 - 2030
    • 3.3.3.1. Active Kinases
    • 3.3.3.2. Ubiquitin
    • 3.3.3.3. Epigenetic
    • 3.3.3.4. Methyltransferases
    • 3.3.3.5. Deacetylases
    • 3.3.3.6. Phosphodiesterases
    • 3.3.3.7. Other Product Types
• 3.4. Market Attractiveness Analysis: Product Type
• 3.5. Global Drug Discovery Enzymes Market Outlook: End User
  • 3.5.1. Introduction / Key Findings
  • 3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By End User, 2018 - 2022
  • 3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
    • 3.5.3.1. Pharmaceutical and Biotechnology Company
    • 3.5.3.2. Research institutes
    • 3.5.3.3. Other end user
• 3.6. Market Attractiveness Analysis: End User

4. Global Drug Discovery Enzymes Market Outlook: Region

• 4.1. Key Highlights
• 4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
• 4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
  • 4.3.1. North America
  • 4.3.2. Europe
  • 4.3.3. East Asia
  • 4.3.4. South Asia and Oceania
  • 4.3.5. Latin America
  • 4.3.6. Middle East & Africa (MEA)
• 4.4. Market Attractiveness Analysis: Region

5. North America Drug Discovery Enzymes Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 5.1. Key Highlights
• 5.2. Pricing Analysis
• 5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 5.3.1. By Country
  • 5.3.2. By Product Type
  • 5.3.3. By End User
• 5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 5.4.1. U.S.
  • 5.4.2. Canada
• 5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product Type, 2023 - 2030
  • 5.5.1. Active Kinases
  • 5.5.2. Ubiquitin
  • 5.5.3. Epigenetic
  • 5.5.4. Methyltransferases
  • 5.5.5. Deacetylases
  • 5.5.6. Phosphodiesterases
  • 5.5.7. Other Product Types
• 5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
  • 5.6.1. Pharmaceutical and Biotechnology Company
  • 5.6.2. Research institutes
  • 5.6.3. Other end user
• 5.7. Market Attractiveness Analysis

6. Europe Drug Discovery Enzymes Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 6.1. Key Highlights
• 6.2. Pricing Analysis
• 6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 6.3.1. By Country
  • 6.3.2. By Product Type
  • 6.3.3. By End User
• 6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 6.4.1. Germany
  • 6.4.2. France
  • 6.4.3. U.K.
  • 6.4.4. Italy
  • 6.4.5. Spain
  • 6.4.6. Russia
  • 6.4.7. T rkiye
  • 6.4.8. Rest of Europe
• 6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product Type, 2023 - 2030
  • 6.5.1. Active Kinases
  • 6.5.2. Ubiquitin
  • 6.5.3. Epigenetic
  • 6.5.4. Methyltransferases
  • 6.5.5. Deacetylases
  • 6.5.6. Phosphodiesterases
  • 6.5.7. Other Product Types
• 6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
  • 6.6.1. Pharmaceutical and Biotechnology Company
  • 6.6.2. Research institutes
  • 6.6.3. Other end user
• 6.7. Market Attractiveness Analysis

7. East Asia Drug Discovery Enzymes Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 7.1. Key Highlights
• 7.2. Pricing Analysis
• 7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 7.3.1. By Country
  • 7.3.2. By Product Type
  • 7.3.3. By End User
• 7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 7.4.1. China
  • 7.4.2. Japan
  • 7.4.3. South Korea
• 7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product Type, 2023 - 2030
  • 7.5.1. Active Kinases
  • 7.5.2. Ubiquitin
  • 7.5.3. Epigenetic
  • 7.5.4. Methyltransferases
  • 7.5.5. Deacetylases
  • 7.5.6. Phosphodiesterases
  • 7.5.7. Other Product Types
• 7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
  • 7.6.1. Pharmaceutical and Biotechnology Company
  • 7.6.2. Research institutes
  • 7.6.3. Other end user
• 7.7. Market Attractiveness Analysis

8. South Asia & Oceania Drug Discovery Enzymes Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 8.1. Key Highlights
• 8.2. Pricing Analysis
• 8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 8.3.1. By Country
  • 8.3.2. By Product Type
  • 8.3.3. By End User
• 8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 8.4.1. India
  • 8.4.2. Southeast Asia
  • 8.4.3. ANZ
  • 8.4.4. Rest of South Asia & Oceania
• 8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product Type, 2023 - 2030
  • 8.5.1. Active Kinases
  • 8.5.2. Ubiquitin
  • 8.5.3. Epigenetic
  • 8.5.4. Methyltransferases
  • 8.5.5. Deacetylases
  • 8.5.6. Phosphodiesterases
  • 8.5.7. Other Product Types
• 8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
  • 8.6.1. Pharmaceutical and Biotechnology Company
  • 8.6.2. Research institutes
  • 8.6.3. Other end user
• 8.7. Market Attractiveness Analysis

9. Latin America Drug Discovery Enzymes Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 9.1. Key Highlights
• 9.2. Pricing Analysis
• 9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 9.3.1. By Country
  • 9.3.2. By Product Type
  • 9.3.3. By End User
• 9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America
• 9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product Type, 2023 - 2030
  • 9.5.1. Active Kinases
  • 9.5.2. Ubiquitin
  • 9.5.3. Epigenetic
  • 9.5.4. Methyltransferases
  • 9.5.5. Deacetylases
  • 9.5.6. Phosphodiesterases
  • 9.5.7. Other Product Types
• 9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
  • 9.6.1. Pharmaceutical and Biotechnology Company
  • 9.6.2. Research institutes
  • 9.6.3. Other end user
• 9.7. Market Attractiveness Analysis

10. Middle East & Africa Drug Discovery Enzymes Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

• 10.1. Key Highlights
• 10.2. Pricing Analysis
• 10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
  • 10.3.1. By Country
  • 10.3.2. By Product Type
  • 10.3.3. By End User
• 10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
  • 10.4.1. GCC
  • 10.4.2. Egypt
  • 10.4.3. South Africa
  • 10.4.4. Northern Africa
  • 10.4.5. Rest of Middle East & Africa
• 10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product Type, 2023 - 2030
  • 10.5.1. Active Kinases
  • 10.5.2. Ubiquitin
  • 10.5.3. Epigenetic
  • 10.5.4. Methyltransferases
  • 10.5.5. Deacetylases
  • 10.5.6. Phosphodiesterases
  • 10.5.7. Other Product Types
• 10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
  • 10.6.1. Pharmaceutical and Biotechnology Company
  • 10.6.2. Research institutes
  • 10.6.3. Other end user
• 10.7. Market Attractiveness Analysis

11. Competition Landscape

• 11.1. Market Share Analysis, 2022
• 11.2. Market Structure
  • 11.2.1. Competition Intensity Mapping By Market
  • 11.2.2. Competition Dashboard
  • 11.2.3. Apparent Product Capacity
• 11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 11.3.1. Sigma-Aldrich Co. LLC.
    • 11.3.1.1. Overview
    • 11.3.1.2. Segments and Product
    • 11.3.1.3. Key Financials
    • 11.3.1.4. Market Developments
    • 11.3.1.5. Market Strategy
  • 11.3.2. Kaneka Corporation
    • 11.3.2.1. Overview
    • 11.3.2.2. Segments and Product
    • 11.3.2.3. Key Financials
    • 11.3.2.4. Market Developments
    • 11.3.2.5. Market Strategy
  • 11.3.3. Actelion Pharmaceuticals Ltd
    • 11.3.3.1. Overview
    • 11.3.3.2. Segments and Product
    • 11.3.3.3. Key Financials
    • 11.3.3.4. Market Developments
    • 11.3.3.5. Market Strategy
  • 11.3.4. Genesis Biotechnology Group
    • 11.3.4.1. Overview
    • 11.3.4.2. Segments and Product
    • 11.3.4.3. Key Financials
    • 11.3.4.4. Market Developments
    • 11.3.4.5. Market Strategy
  • 11.3.5. Suven Life Sciences Limited
    • 11.3.5.1. Overview
    • 11.3.5.2. Segments and Product
    • 11.3.5.3. Key Financials
    • 11.3.5.4. Market Developments
    • 11.3.5.5. Market Strategy
  • 11.3.6. Enzo Life Sciences, Inc.
    • 11.3.6.1. Overview
    • 11.3.6.2. Segments and Product
    • 11.3.6.3. Key Financials
    • 11.3.6.4. Market Developments
    • 11.3.6.5. Market Strategy
  • 11.3.7. Merck KGaA
    • 11.3.7.1. Overview
    • 11.3.7.2. Segments and Product
    • 11.3.7.3. Key Financials
    • 11.3.7.4. Market Developments
    • 11.3.7.5. Market Strategy
  • 11.3.8. Apeiron Biologics
    • 11.3.8.1. Overview
    • 11.3.8.2. Segments and Product
    • 11.3.8.3. Key Financials
    • 11.3.8.4. Market Developments
    • 11.3.8.5. Market Strategy
  • 11.3.9. STORM Therapeutics
    • 11.3.9.1. Overview
    • 11.3.9.2. Segments and Product
    • 11.3.9.3. Key Financials
    • 11.3.9.4. Market Developments
    • 11.3.9.5. Market Strategy
  • 11.3.10. Thermo Fisher Scientific
    • 11.3.10.1. Overview
    • 11.3.10.2. Segments and Product
    • 11.3.10.3. Key Financials
    • 11.3.10.4. Market Developments
    • 11.3.10.5. Market Strategy
  • 11.3.11. Abcam
    • 11.3.11.1. Overview
    • 11.3.11.2. Segments and Product
    • 11.3.11.3. Key Financials
    • 11.3.11.4. Market Developments
    • 11.3.11.5. Market Strategy

12. Appendix

• 12.1. Research Methodology
• 12.2. Research Assumptions
• 12.3. Acronyms and Abbreviations